Celator Pharmaceuticals Inc., of Ewing, N.J., said the independent data and safety monitoring board (DSMB) for their phase III study of CPX-351 (cytarabine:daunorubicin) liposome injection vs. the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML) has completed a planned safety review and recommended that the study should continue without any modifications.